Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Coates

Pediatric Hematology-Oncology Los Angeles, CA Medical Doctor

NPI 1790885697 CMS profile 36461

4650 W Sunset Blvd, Los Angeles, CA 90027

Open in the dashboard

General payments

$99,396

81 records reported · program years 2019–2025

Research payments

$3,432

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,950,751 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Thomas Coates of Los Angeles, CA is reported in the CMS Open Payments database as having received $99,396 across 81 general payments and $3,432 in research payments paid to them. Separately, studies naming them as principal investigator received $1,950,751 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,864 9
2024 General $10,738 7
2023 General $11,085 4
2022 General $19,947 16
2021 General $14,714 9
2020 General $15,093 17
2019 General $21,956 19
2019 Research $3,432 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Coates
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Thomas Coates were reported at $5,864. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Thomas Coates Pediatric Hematology-Oncology median Middle half National median
2019 $21,956 $184 $69–$2,094 $163
2020 $15,093 $220 $37–$3,941 $114
2021 $14,714 $366 $63–$4,909 $132
2022 $19,947 $181 $66–$2,775 $149
2023 $11,085 $175 $62–$2,600 $160
2024 $10,738 $227 $66–$2,992 $164
2025 $5,864 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Celgene Corporation $35,765 20 payments
  2. Chiesi USA, Inc. $32,605 21 payments
  3. Agios Pharmaceuticals, Inc. $20,517 29 payments
  4. Vifor (International) Ltd. $4,439 4 payments
  5. Apo-Pharma Inc. $3,360 1 payment
  6. E.R. Squibb & Sons, L.L.C. $2,500 1 payment
  7. Novo Nordisk Inc $154 2 payments
  8. Global Blood Therapeutics, Inc. $24 1 payment
  9. Portola Pharmaceuticals, Inc. $20 1 payment
  10. Sobi, Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $52,620 25 payments
  2. Honoraria $22,133 8 payments
  3. Travel and Lodging $8,053 15 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,360 3 payments
  5. Education $5,605 1 payment
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,000 1 payment
  7. Food and Beverage $1,626 28 payments
Products named General payments · program years 2019–2025
  1. REBLOZYL $21,672 11 payments
  2. PYRUKYND $13,034 19 payments
  3. Luspatercept $11,093 7 payments
  4. FERRIPROX Hematology, Disease $7,497 3 payments
  5. TIBSOVO $7,482 10 payments
  6. FERRIPROX Treat Iron Overload From Thalassemia, Sickle Cell Or Another Anemia $7,024 2 payments
  7. FERRIPROX Transfusional Iron Overload Due To Thalassemia Syndromes $5,334 10 payments
  8. FERRIPROX Iron Chelator $3,360 1 payment
  9. Veltassa $749 1 payment
  10. Alhemo $29 1 payment
  11. Other $57 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Celgene Corporation $3,432 2 payments

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$2,656

Medicare's payments for the services billed

Medicare patients

13

Average age 35

Services billed

29

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Ischemic heart disease 0%
COPD 0%
Cancer 0%
Depression 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PYRUKYND
  • Agios Pharmaceuticals, Inc. $3,113
$3,113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record